NeuroSense Therapeutics Ltd. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for NRSN, updated each market day.
NRSN AI Sentiment
AI sees no strong directional signal for NeuroSense Therapeutics Ltd. Ordinary Shares stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Exchange
Market Cap
$12,747,181
Cap Tier
Employees
16
Listed Since
Dec. 9, 2021
Website
NRSN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NRSN Volatility
NeuroSense Therapeutics Ltd. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
